论文部分内容阅读
以BRD－2疫苗株制备的三批风疹疫苗（滴度分别为5．25、5．75、5．50TCID50／0．5ml），分别在风疹抗体阴性的799名2～6岁儿童和167名女青年中做了临床反应性和免疫原性观察。在儿童中，三批疫苗的发热率分别为2．43％、0％和2．17％，对照组为2．78％，无高热反应。在女青年中发热率分别为0％、1．72％和2．08％，对照组为2．0％，未出现高于38℃的中热反应，未见有皮疹、淋巴结肿大、咽喉红肿、关节痛等反应。在儿童中，三批疫苗的抗体阳转率为100％、98．67％和100％，GMT±SD分别为57.67±2．347，102．54±2．33和110．41±1．94。在女青年中，抗体阳转率分别为100％、98．28％和100％，GMT±SD分别为58．44±2．17、65．55±2．46和65．88±2．1。疫苗稀释100倍后，在儿童中其抗体阳转率可达91．91％，GMT46．9±3．543，疫苗稀释1万倍后（约32TCID50）其抗体阳转率仍有61．7％。
Three batches of rubella vaccine (titers of 5.25, 5.75 and 5.50 TCID50 / 0.5 ml respectively) prepared with the BRD-2 vaccine strain were administered to 799 children aged 2-6 years and 167 Young women made clinical reactivity and immunogenicity observations. Among children, the fever rates for the three batches of vaccines were 2.43%, 0% and 2.17% respectively, compared with 2.78% in the control group, with no hyperthermia response. In young women, the rates of fever were 0%, 1.72% and 2.08%, respectively. The control group was 2.0%. There was no moderate fever above 38 ℃. No rash, lymphadenopathy and throat Redness, joint pain and other reactions. Among children, the antibody positive rates for the three batches of vaccines were 100%, 98.67%, and 100% with GMT ± SD of 57.67 ± 2.347, 102.54 ± 2.33 and 110.41 ± 1.94, respectively . In young women, the antibody positive rates were 100%, 98.28% and 100%, respectively, and GMT ± SD were 58.44 ± 2.17, 65.55 ± 2.46 and 65.88 ± 2.1 . After the vaccine was diluted 100-fold, the antibody positive rate in children was 91.91% and the GMT was 46.9 ± 3.543. After the vaccine was diluted by 10,000 times (about 32TCID50), the antibody positive rate was still 61.7% .